Latest Articles
New Perspectives on the Use of Resveratrol in the Treatment of Metabolic and Estrogen-Dependent Conditions Through Hormonal Modulation and Anti-Inflammatory Effects.
Estrogen-dependent conditions, such as endometriosis, adenomyosis, lipedema, polycystic ovary syndrome, and breast cancer, are intimately involved with hormonal changes related to estrogen and their receptors. These conditions can be expressed …
Published: Aug. 27, 2025, midnight
Real time alert setup for GTLB performance - Jobs Report & Daily Entry Point Trade Alerts - Newser
Real time alert setup for GTLB performance - Jobs Report & Daily Entry Point Trade Alerts Newser
Published: Aug. 26, 2025, 11:54 p.m.
Snag $125 off the Dyson Airwrap bundle ahead of Prime Day - Mashable
Snag $125 off the Dyson Airwrap bundle ahead of Prime Day Mashable
Published: Aug. 26, 2025, 10 p.m.
The new Dyson Airstrait is finally available for purchase - Mashable
The new Dyson Airstrait is finally available for purchase Mashable
Published: Aug. 26, 2025, 10 p.m.
Advanced Fellowship in Minimally Invasive Gynecological Surgery (AF MIGS) - VA.gov Home | Veterans Affairs
Advanced Fellowship in Minimally Invasive Gynecological Surgery (AF MIGS) VA.gov Home | Veterans Affairs
Published: Aug. 26, 2025, 9:45 p.m.
Genmab's Rina-S: A Game-Changer in Endometrial Cancer and a Catalyst for Shareholder Value - AInvest
Genmab's Rina-S: A Game-Changer in Endometrial Cancer and a Catalyst for Shareholder Value AInvest
Published: Aug. 26, 2025, 7:31 p.m.
Genmab's Rina-S: A Breakthrough in Endometrial Cancer and a Catalyst for Shareholder Value - AInvest
Genmab's Rina-S: A Breakthrough in Endometrial Cancer and a Catalyst for Shareholder Value AInvest
Published: Aug. 26, 2025, 5:39 p.m.
Analyzing ImmunityBio Inc. with multi timeframe charts - July 2025 Institutional & Risk Controlled Daily Plans - Newser
Analyzing ImmunityBio Inc. with multi timeframe charts - July 2025 Institutional & Risk Controlled Daily Plans Newser
Published: Aug. 26, 2025, 4:22 p.m.
Olaparib Maintenance in Advanced Endometrial Cancer Trial - BIOENGINEER.ORG
Olaparib Maintenance in Advanced Endometrial Cancer Trial BIOENGINEER.ORG
Published: Aug. 26, 2025, 3:07 p.m.
Genmab's Rina-S: A Breakthrough in Gynecologic Oncology and a Catalyst for Value Creation - AInvest
Genmab's Rina-S: A Breakthrough in Gynecologic Oncology and a Catalyst for Value Creation AInvest
Published: Aug. 26, 2025, 1:01 p.m.
Link copied to clipboard!